Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis

Journal of the Neurological Sciences

Volumn 252, Issue 1, 2007, Pages 45-48

  Ichiyama, Takashi ^a   Siba, Peter ^b   Suarkia, Dagwin ^b   Takasu, Toshiaki ^c   Miki, Kenji ^c   Kira, Ryutaro ^d   Kusuhara, Koichi ^d   Hara, Toshiro ^d   Toyama, Jun ^e   Furukawa, Susumu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e NISHI NIIGATA CHUO NATIONAL HOSPITAL   (Japan)

Author keywords

Blood brain barrier; MMP 9; Subacute sclerosing panencephalitis; TIMP 1

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CELL; BLOOD CHEMISTRY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; JAPAN; MALE; MEMBRANE PERMEABILITY; PAPUA NEW GUINEA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBACUTE SCLEROSING PANENCEPHALITIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-CULTURAL COMPARISON; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JAPAN; MALE; MATRIX METALLOPROTEINASE 9; NEW GUINEA; SUBACUTE SCLEROSING PANENCEPHALITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33845404877     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.10.005     Document Type: Article

References (38)

1. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C., et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72 (1997) 155-161
2. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253 (2003) 269-285
3. Lukes A., Mun-Bryce S., Lukes M., and Rosenberg G.A. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 19 (1999) 267-284
4. Murphy G., and Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol 15 (1997) 511-518
5. Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., and Dayer J.M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96 (1995) 2304-2310
6. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53 (1999) 1397-1401
7. Avolio C., Ruggieri M., Giuliani F., Liuzzi G.M., Leante R., Riccio P., et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136 (2003) 46-53
8. Dubois B., Leary S.M., Nelissen I., Opdenakker G., Giovannoni G., and Thompson A.J. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1α. J Neurol 250 (2003) 1037-1043
9. Waubant E., Goodkin D., Bostrom A., Bacchetti P., Hietpas J., Lindberg R., et al. IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60 (2003) 52-57
10. Yushchenko M., Mäder M., Elitok E., Bitsch A., Dressel A., Tumani H., et al. Interferon-β-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 250 (2003) 1224-1228
11. Blanco Y., Saiz A., Carreras E., and Graus F. Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. J Neuroimmunol 153 (2004) 190-194
12. Karabudak R., Kurne A., Guc D., Sengelen M., Canpinar H., and Kansu E. Effect of interferon β-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol 251 (2004) 279-283
13. Mirowska D., Wicha W., Czlonkowski A., Czlonkowska A., and Weber F. Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 146 (2004) 171-175
14. Sastre-Garriga J., Comabella M., Brieva L., Rovira A., Tintore M., and Montalban X. Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler 10 (2004) 376-380
15. Abraham M., Shapiro S., Karni A., Weiner H.L., and Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 163 (2005) 157-164
16. Rosenberg G.A. Matrix metalloproteinases biomarkers in multiple sclerosis. Lancet 365 (2005) 1291-1293
17. Ribatti D., Marimpietri D., Pastorino F., Brignole C., Nico B., Vacca A., et al. Angiogenesis in neuroblastoma. Ann NY Acad Sci 1028 (2004) 133-142
18. Lee J.M., Yin K., Hsin I., Chen S., Fryer J.D., Holtzman D.M., et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci 229-230 (2005) 249-254
19. Ichiyama T., Kajimoto M., Suenaga N., Maeba S., Matsubara T., and Furukawa S. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. J Neuroimmunol 172 (2006) 182-186
20. Lucas K.M., Sanders R.C., Rongap A., Rongap T., Pinai S., and Alpers M.P. Subacute sclerosing panencephalitis (SSPE) in Papua New Guinea: a high incidence in young children. Epidemiol Infect 108 (1992) 547-553
21. Takasu T., Mgone J.M., Mgone C.S., Miki K., Komase K., Namae H., et al. A continuing high incidence of subacute sclerosing panencephalitis (SSPE) in the Eastern Highlands of Papua New Guinea. Epidemiol Infect 131 (2003) 887-898
22. CDC. Subacute sclerosing panencephalitis surveillance - United States. MMWR Morb Mortal Wkly Rep 31 (1982) 585-588
23. Dyken P.R. Subacute sclerosing panencephalitis. Current status. Neurol Clin 3 (1985) 179-196
24. Editorial. SSPE in the developing world. Lancet 336 (1990) 600
25. Jabbour J.T., Duenas D.A., and Modlin J. SSPE: clinical staging, course, and frequency, 1975. Arch Neurol 32 (1975) 493-494
26. Ichiyama T., Hayashi T., and Furukawa S. Subacute sclerosing panencephalitis. Neurology 48 (1997) 1142-1143
27. Mehta P.D., Kulczycki J., Mehta S.P., Coyle P.K., and Wisniewski H.M. Increased levels of interleukin-1β and soluble intercellular adhesion molecule-1 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis. J Infect Dis 175 (1997) 689-692
28. Tekgül H., Tutuncuoglu S., Kutukçuler N., Dizdarer G., and Huseyinov A. Lymphocyte subsets and inflammatory mediators in patients with subacute sclerosing panencephalitis. J Child Neurol 14 (1999) 418-421
29. Haspolat S., Anlar B., Köse G., Coskun M., and Yegin O. Interleukin-1β, interleukin-1 receptor antagonist levels in patients with subacute sclerosing panencephalitis and the effects of different treatment protocols. J Child Neurol 16 (2001) 417-420
30. Mistchenko A.S., Fornari M.C., Viegas M., Barrero P.R., and Diez R.A. Detection of interleukin 10 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis. J NeuroVirol 11 (2005) 66-69
31. Ichiyama T., Siba P., Suarkia D., Reeder J., Takasu T., Miki K., et al. Analysis of serum and cerebrospinal fluid cytokine levels in subacute sclerosing panencephalitis in Papua New Guinea. Cytokine 33 (2006) 17-20
32. Welgus H.G., Campbell E.J., Cury J.D., Eisen A.Z., Senior R.M., Wilhelm S.M., et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest 186 (1990) 1496-1502
33. Leppert D., Waubant E., Galardy R., Bunnett N.W., and Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154 (1995) 4379-4389
34. Rosenberg G.A., Dencoff J.E., Correa Jr. N., Reiners M., and Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46 (1996) 1626-1632
35. Chandler S., Coates R., Gearing A., Lury J., Wells G., and Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201 (1995) 223-226
36. Hartung H.P., and Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107 (2000) 140-147
37. Newman T.A., Woolley S.T., Hughes P.M., Sibson N.R., Anthony D.C., and Perry V.H. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124 (2001) 2203-2214
38. Anlar B., Söylemezo{eth}lu F., Aysun S., Köse G., Belen D., and Yalaz K. Tissue inflammatory response in subacute sclerosing panencephalitis (SSPE). J Child Neurol 16 (2001) 895-900